Welcome to our dedicated page for MESOBLAST SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESOBLAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESOBLAST's regulatory disclosures and financial reporting.
Mesoblast Ltd director Jane Catherine Bell has filed an initial Form 3 reporting her equity interests in the company. The filing lists multiple options to buy Ordinary Shares, including options over 108,910 shares at an exercise price of 0.3600 per share expiring on 2030-10-11, and options over 64,103 shares at an exercise price of 0.9700 per share expiring on 2031-08-26. It also reports indirect ownership of 622,492 Ordinary Shares held by Ms. Bell and Geoffrey Arthur Bell as trustees for Ms. Bell's self-managed superannuation fund.
Mesoblast Ltd filed a Form 3 identifying James Michael Obrien, Chief Financial Officer, as a reporting person for MESO. The filing lists no equity or derivative transactions and shows no buy, sell, acquire, dispose, or other activity in the summarized data.
Mesoblast Ltd director and Chief Medical Officer Eric Allen Rose has filed an initial Form 3 detailing his equity interests in the company. He directly holds 6,034,554 Ordinary Shares and an additional 714,720 Ordinary Shares, which are represented by American Depositary Shares.
He also reports multiple option awards over Ordinary Shares, including 820,000 underlying shares at an exercise price of $2.46 per share expiring in 2032, and other grants at exercise prices of $0.35, $0.36, $0.97, $1.01, and $1.81 with expirations between 2026 and 2031. Several recent option grants vest only if Mr. Rose achieves specified milestones.
Mesoblast Limited has filed a Form 6-K highlighting plans for its inaugural R&D Day on April 8, 2026, in New York City. The event will run from 8:00am to 11:00am EST and be webcast live for global access.
Senior leadership and external experts will present on corporate strategy, commercialization of flagship product Ryoncil®, and multi-billion-dollar pipeline opportunities in inflammatory pain and cardiovascular disease. Mesoblast will also unveil new technology intended to support the next era of cellular medicines.
The disclosure reiterates that Mesoblast develops allogeneic cellular therapies for severe inflammatory conditions, including FDA-approved Ryoncil® for pediatric steroid-refractory acute graft versus host disease, and is advancing remestemcel-L and rexlemestrocel-L programs with global partnerships, extensive patents, and proprietary large-scale manufacturing.
Mesoblast Ltd director George Gregory filed an initial Form 3 detailing his derivative holdings in MESO. The filing lists indirect warrants over 6,830,602 ordinary shares at an exercise price of $2.86 expiring in 2028, plus direct warrants over 200,000 ADS at $9.06 and 1,600,000 ordinary shares or ADS at $2.50 expiring between 2028 and 2029.
He also holds three option tranches over 66,667, 66,667 and 66,666 ordinary shares at $1.72 per share, which become exercisable between 2026 and 2028 and expire in 2032. The Form 3 reports these existing positions and does not show new purchases or sales.
Mesoblast Limited reported a change in director Gregory George’s holdings following on-market purchases of its securities in early March 2026. Across 3–6 March 2026, he acquired 5,644,192 ordinary shares and 542,633 American Depositary Shares (ADS) for total consideration of US$16,370,330.90.
Each ADS represents a beneficial interest in 10 ordinary shares. George’s interests are held both directly and indirectly, including through JP Morgan Nominees Australia Pty Limited and G to the Fourth Investments, LLC, as well as ADSs where family members have granted him power of attorney.
After these transactions, his direct holdings remain at 5 ordinary shares, 12,829,328 ADSs, 200,000 warrants convertible into ADS, and 1,600,000 warrants to acquire ordinary shares. Indirectly, he now holds 5,644,192 ordinary shares, 14,415,410 ADSs, and 6,830,602 warrants to acquire ordinary shares.
Mesoblast Limited reported that Dr. Teresa Montagut, MD, PhD, has been appointed to the newly created role of Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose. She will lead medical affairs, clinical collaborations, investigator-initiated trials, and engagement with healthcare professionals.
Dr. Montagut previously held senior medical and development roles at Regeneron, Novartis, Genentech, and Atara Biotherapeutics, and trained at leading U.S. institutions including Memorial Sloan Kettering Cancer Center. The company highlights her importance in advancing Ryoncil®, its FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease, and in expanding Mesoblast’s broader inflammatory disease and cell therapy pipeline.
Mesoblast Ltd Amendment reports that Gregory George beneficially owns 288,522,256 ordinary shares, representing 22.36% of the class as of March 6, 2026, based on 1,290,302,187 ordinary shares outstanding as of March 6, 2025.
The filing breaks down holdings: Gregory George directly holds 138,723,887 shares (including 10,430,602 warrants and 128,293,285 ADRs) and reports shared voting/dispositive power over additional shares held by G to the Fourth Investments, LLC (135,798,292) and by his sons James George (8,000,000) and Grant George (6,000,000). The filing lists James George with 8,000,000 shares (0.62%), Grant George with 6,000,000 shares (0.47%), and G to the Fourth Investments, LLC with 135,798,292 shares (10.52%).
Mesoblast Limited reported a sharp jump in activity for the half-year ended December 31, 2025, as the U.S. launch of Ryoncil drove total revenue to US$51.3 million, up from US$3.2 million a year earlier. Net loss narrowed to US$40.2 million from US$47.9 million, helped by high Ryoncil gross margins and tight cost control.
Ryoncil generated US$48.7 million of revenue and a gross profit of US$44.2 million, funding increased R&D spending of US$46.2 million on late-stage programs in chronic low back pain and heart failure. The company ended the period with cash of US$129.975 million, access to a US$125.0 million five-year credit line, and guided full-year fiscal 2026 Ryoncil net revenue to US$110–120 million.
Mesoblast Limited reported a sharply higher top line for the six months ended December 31, 2025, driven by the U.S. launch of Ryoncil®. Total revenue rose to $51.3 million from $3.2 million a year earlier, including $48.7 million of net product sales and $2.7 million of TEMCELL royalties.
The company still posted a net loss of $40.2 million, improving from a $47.9 million loss, with basic and diluted loss per share of 3.11 cents versus 4.20 cents. Operating cash outflow was $30.3 million, and period-end cash and cash equivalents were $130.0 million.
In December 2025 Mesoblast put in place a new $125.0 million, five-year credit-line facility from its largest shareholder, drawing $75.0 million to fully repay its Oaktree senior loan and partially repay its NovaQuest facility. Net debt, including leases and warrant liabilities, moved from a net cash position of $27.7 million to net debt of $19.3 million, while intangible assets related to Ryoncil® and other pipeline programs remained substantial.